Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Medications in this class such as semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) act by mimicking GLP-1's effects: They reduce appetite and increase feelings of fullness
The semaglutide dosage calculator can confirm the conversion for any concentration
The allure of Ozempics weight loss potential has come at a high cost
It provides critical data on liver health, detoxification, and metabolic disorders
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
